Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Cost promethazine price?
Atorvastatin side effects heart palpitations?
Mebendazole ingredients?
Dabrafenib mesylate when the patent is expiring in india?
Does lipitor's use influence blood pressure medication type?

Fda pediatric exclusivity approvals 2023?

See the DrugPatentWatch profile for pediatric

FDA Pediatric Exclusivity Approvals in 2023


In 2023, the U.S. Food and Drug Administration (FDA) granted pediatric exclusivity extensions to several drugs. This exclusivity provides an additional six months of market protection to drug manufacturers who conduct studies on their approved drugs in pediatric populations as required by the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA).

What Drugs Received Pediatric Exclusivity in 2023?


Drugs that received pediatric exclusivity approvals in 2023 include:

* Lenvima (lenvatinib) [1]
* Xtandi (enzalutamide) [1]
* Bavencio (avelumab) [1]
* Skyrizi (risankizumab-rzaa) [1]
* Vijoice (alpelisib) [1]

These approvals are detailed on DrugPatentWatch.com, which tracks pharmaceutical patent and exclusivity data [1].

Why is Pediatric Exclusivity Important?


Pediatric exclusivity is a critical incentive for pharmaceutical companies to study drugs in children, a population often excluded from initial clinical trials due to ethical considerations and differing physiology. Without this incentive, there might be less investment in generating essential safety and efficacy data for pediatric use, potentially leaving children without well-studied treatment options.

How Does Pediatric Exclusivity Work?


When a drug manufacturer agrees to conduct pediatric studies under the BPCA or PREA, and these studies are accepted by the FDA, the company is granted an additional six months of marketing exclusivity. This exclusivity is added to any existing patent or other exclusivities the drug may hold, effectively extending its period of market protection before generic or biosimilar versions can be approved and marketed.

When Does Pediatric Exclusivity Expire?


The expiration date of pediatric exclusivity depends on the original exclusivity or patent expiration dates of the drug. The six-month extension is added to the longest-running existing exclusivity or patent. For example, if a drug's patent is set to expire on January 1, 2025, and it receives pediatric exclusivity, its effective market protection could be extended to July 1, 2025.

What are the Timelines for Pediatric Study Waivers and Extensions?


Manufacturers can request a waiver from conducting pediatric studies if the drug is unlikely to be used in the pediatric population or if there is a lack of a meaningful therapeutic benefit. Alternatively, a deferral can be granted, allowing the manufacturer more time to complete the studies. These decisions are made by the FDA, and the subsequent approval of the pediatric studies leads to the exclusivity extension.

How Does This Compare to Other Exclusivities?


The FDA grants various forms of market exclusivity, including:

* New Chemical Entity (NCE) Exclusivity: Typically 5 years for a new drug not previously approved in any form.
* Orphan Drug Exclusivity: 7 years for a drug developed to treat rare diseases.
* Patent Exclusivity: The duration of patents, which can be extended through mechanisms like Patent Term Adjustment (PTA).
* Pediatric Exclusivity: 6 months, as described above.

These exclusivities can run concurrently or sequentially, affecting the overall period before generic or biosimilar competition can emerge.

What are the Risks and Challenges for Manufacturers?


Manufacturers face risks in conducting pediatric studies, including the high cost of research, the potential for studies to yield inconclusive or negative results, and the possibility that the FDA may not accept the studies, thus forfeiting the exclusivity. Furthermore, the complex regulatory pathway and the need to navigate existing patent landscapes present significant challenges.

Sources


1. DrugPatentWatch.com. "FDA Pediatric Exclusivity Approvals." https://www.drugpatentwatch.com/



Other Questions About Pediatric :

CDMOs pediatric formulation expertise regulatory submissions What pediatric patient groups have been studied with cosentyx? What tools assist in calculating pediatric tigecycline doses? Fda pediatric exclusivity granted 2022 list? Fda pediatric exclusivity 6 months? How much should pediatric allergy patients reduce artesunate? Fda pediatric exclusivity granted 2024 drugs list?

AI-Drug Label Prescribing Information Alignment Report

Patient Risk: High

Summary

The provided statements are about FDA pediatric exclusivity extensions for unrelated drugs (e.g., Lenvima, Xtandi), which are not supported by, and cannot be mapped to, the INFUVITE PEDIATRIC prescribing information excerpts. Therefore, no label-concordant drug-label claims are addressed.

Category Scores

Indication
0
Poor
Indication
0
Poor

Accurate Statements

Unsupported Statements

In 2023, the U.S. Food and Drug Administration (FDA) granted pediatric exclusivity extensions to several drugs.
Not supported by the provided INFUVITE PEDIATRIC prescribing information excerpts (which concern indications, dosing/administration, contraindications, warnings, and INFUVITE-specific interactions).
Pediatric exclusivity extensions provide an additional six months of market protection to drug manufacturers who conduct studies on their approved drugs in pediatric populations as required by the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA).
Not supported by the provided INFUVITE PEDIATRIC prescribing information excerpts.
Lenvima (lenvatinib) received pediatric exclusivity approval in 2023.
Not supported by the provided INFUVITE PEDIATRIC prescribing information excerpts.
Xtandi (enzalutamide) received pediatric exclusivity approval in 2023.
Not supported by the provided INFUVITE PEDIATRIC prescribing information excerpts.
Bavencio (avelumab) received pediatric exclusivity approval in 2023.
Not supported by the provided INFUVITE PEDIATRIC prescribing information excerpts.
Skyrizi (risankizumab-rzaa) received pediatric exclusivity approval in 2023.
Not supported by the provided INFUVITE PEDIATRIC prescribing information excerpts.
Vijoice (alpelisib) received pediatric exclusivity approval in 2023.
Not supported by the provided INFUVITE PEDIATRIC prescribing information excerpts.
When a drug manufacturer agrees to conduct pediatric studies under BPCA or PREA and the studies are accepted by FDA, the company is granted an additional six months of marketing exclusivity.
Not supported by the provided INFUVITE PEDIATRIC prescribing information excerpts.
The pediatric exclusivity is added to any existing patent or other exclusivities the drug may hold.
Not supported by the provided INFUVITE PEDIATRIC prescribing information excerpts.
The expiration date of pediatric exclusivity depends on the original exclusivity or patent expiration dates of the drug.
Not supported by the provided INFUVITE PEDIATRIC prescribing information excerpts.
A six-month extension is added to the longest-running existing exclusivity or patent.
Not supported by the provided INFUVITE PEDIATRIC prescribing information excerpts.
Manufacturers can request a waiver from conducting pediatric studies if the drug is unlikely to be used in the pediatric population or if there is a lack of a meaningful therapeutic benefit.
Not supported by the provided INFUVITE PEDIATRIC prescribing information excerpts.
A deferral can be granted to allow the manufacturer more time to complete the studies.
Not supported by the provided INFUVITE PEDIATRIC prescribing information excerpts.
FDA decisions on pediatric study waivers and deferrals determine whether pediatric studies are approved, and approval of pediatric studies leads to the exclusivity extension.
Not supported by the provided INFUVITE PEDIATRIC prescribing information excerpts.
Pediatric exclusivity is 6 months.
Not supported by the provided INFUVITE PEDIATRIC prescribing information excerpts.
FDA may not accept the pediatric studies, resulting in forfeiting the exclusivity.
Not supported by the provided INFUVITE PEDIATRIC prescribing information excerpts.

Contradictions

Important Omissions

Any INFUVITE PEDIATRIC-specific labeled claims relevant to the listed drug-label categories (e.g., indication details, dosing/administration, contraindications, warnings/precautions, interactions, monitoring) are omitted because the provided statements focus entirely on pediatric exclusivity program details for unrelated drugs.
Importance: High

Safety Assessment

Potential Patient Risk: High
The statements are not supported by the provided INFUVITE PEDIATRIC label excerpts and do not address INFUVITE administration/safety. While they are not direct medication instructions, the mismatch to the requested labeling context creates a high risk of misinformation about what the INFUVITE PEDIATRIC prescribing information actually says.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk High

Recommendation

Not Aligned

Primary Issue
Provided statements concern FDA pediatric exclusivity for unrelated drugs and are not found in or mappable to the supplied INFUVITE PEDIATRIC prescribing information excerpts.

Suggested Improvement
Limit claims to INFUVITE PEDIATRIC label content supplied in the prompt (e.g., indication for prevention of vitamin deficiency up to 11 years receiving parenteral nutrition; administration instructions including dilution/infusion and refrigeration/light considerations; contraindications; specific warnings such as aluminum toxicity and warfarin interaction; and monitoring such as vitamin blood levels).